Avadel Pharmaceuticals

281 articles about Avadel Pharmaceuticals

• Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/4/2023

  Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, provided a corporate update and announced its financial results for the first quarter ended March 31, 2023.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2023

  5/3/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to twenty one new employees to purchase an aggregate of 193,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension as the First and Only Once-at-Bedtime Oxybate for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy

  5/1/2023

  Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to LUMRYZ, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 20, 2023

  4/20/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to thirty two new employees to purchase an aggregate of 236,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

  4/10/2023

  Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference on Monday, April 17 at 9:30 a.m. ET.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2023

  4/3/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 46,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30

  3/30/2023

  Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2022.

• Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/30/2023

  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2022.

• Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

  3/30/2023

  Avadel Pharmaceuticals plc announced the pricing of an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share in the form of American Depositary Shares and of 4,705,882 Series B Non-Voting Convertible Preferred Shares, convertible into Ordinary Shares on a one-for-one basis.

• Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

  3/29/2023

  Avadel Pharmaceuticals plc announced its entry into a royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million to support the potential commercialization of LUMRYZ™ for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.

• Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

  3/29/2023

  Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that it is commencing an underwritten public offering of its ordinary shares, nominal value $0.01 per share in the form of American Depositary Shares.

• Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

  3/22/2023

  Avadel Pharmaceuticals plc today announced that the U.S. Food and Drug Administration (“FDA”) has approved its Pre-Launch Activities Importation Requests (PLAIR) for LUMRYZ.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023

  3/21/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to one new employee to purchase 15,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension

  3/2/2023

  Avadel Pharmaceuticals plc announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 16, 2023

  2/16/2023

  Avadel Pharmaceuticals plc announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two new employees to purchase an aggregate of 28,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

  2/8/2023

  Avadel Pharmaceuticals plc announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2023

  2/3/2023

  Avadel Pharmaceuticals plc today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to two (2) new employees to purchase an aggregate of 38,000 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates

  1/24/2023

  Avadel Pharmaceuticals plc today announced the publication of real-world data describing the risk of accidental dosing errors with immediate-release twice-nightly oxybate.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jan 23, 2023

  1/23/2023

  Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to three new employees to purchase an aggregate of 40,500 ordinary shares under Avadel’s 2021 Inducement Plan.

• Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  1/10/2023

  Avadel Pharmaceuticals plc today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase an aggregate of 105,000 ordinary shares under Avadel’s 2021 Inducement Plan.